Fig. 3.
![Fig. 3. EFS according to the risk group: low-risk group (no mediastinal or visceral involvement, LDH <800 UI/L [—]) and high-risk group (mediastinal and/or visceral involvement and/or LDH ≥800 UI/L [···]) of the patients enrolled in the HM 89 and HM 91 studies.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/92/10/10.1182_blood.v92.10.3591/4/blod42230003x.jpeg?Expires=1735577224&Signature=MZfK5BGmkpKVYMSpjJdpzWpTwBNWCbPSLa1p~Os52~P~vyMYYVB7XpAhJItIhXn95y5x7PJhGSiZUTViVDt2Mnq-vAQsqu4xtw5yN1JGv8FiGKI0YldmivMKJ7f~UYRkfVHs3v3P232JUznHn2OfebiMKbg02h71boqPSasSX~taM-nEB142TDe1rb2XTRs6D0KN0zblCF9M56jW2Zx6A52oh~O32Jm82z2EVKbrvUPmiO8l4VY1YLg2tibloHOyq1WkfQ5zKR4aNb9jD1u2JpITmeLqCNpDVAUMSEbV9aiQNF7CnyQUJ68F45f1YepBdGzOUuOLeoh53MFA6Ca9ng__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
EFS according to the risk group: low-risk group (no mediastinal or visceral involvement, LDH <800 UI/L [—]) and high-risk group (mediastinal and/or visceral involvement and/or LDH ≥800 UI/L [···]) of the patients enrolled in the HM 89 and HM 91 studies.
